AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02782936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gas mask
Description: During the conditions that involved a gas mask, the measurement of the work of breathing is achieved with a oesophageal catheter and two disposable pneumotachs. While the oesophageal catheter has been fixed to the mandibular with an hypo-allergic tape, the two pneumotachs are hooked respectively on the canister and exhalation port of the gas mask. Investigators have induced the hypoxemia with a mixture nitreous and medical gas in a plastic bag that has been setted up to the canister. The FiO2 level has been kept to 14 percent.
Study NCT03936621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: To evaluate the efficacy of 3.6 g omega 3 fatty acid supplements (2.4 g EPA + 1.2 g DHA)/day for 6 months versus no treatment at reducing the level of C-reactive protein (CRP) in ever smokers at high risk of lung cancer. The primary endpoint of the study is reduction of CRP.
Study NCT03936621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3 fatty acid
Description: To evaluate the efficacy of 3.6 g omega 3 fatty acid supplements (2.4 g EPA + 1.2 g DHA)/day for 6 months versus no treatment at reducing the level of C-reactive protein (CRP) in ever smokers at high risk of lung cancer. The primary endpoint of the study is reduction of CRP.
Study NCT01172197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Femoral bolus 150μM followed by femoral infusion 400μM
Study NCT01172197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Bolus and infusion
Study NCT01111942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radiation combined with weekly carboplatin
Description: recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;~Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.~Induction Triple Therapy Treatment with TPF:~Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta\* 6 mg SC Day 5 (\*Neupogen may be substituted at the investigator's discretion)
Study NCT01111942 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conservation surgery
Description: Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
Study NCT00187096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2
Description: See Detailed Description section for additional details of treatment interventions.
Study NCT00187096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Infusion
Description: See Detailed Description section for additional details of treatment interventions.
Study NCT00187096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS System
Description: See Detailed Description section for additional details of treatment interventions.
Study NCT03883191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder
Description: Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
Study NCT03883191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking 1 pack of placebo powder three times a day before meals for three months.
Study NCT00861250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib + dexamethasone
Description: Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
Study NCT01150175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endomyocardial Injection of Autologous Bone Marrow Cells
Description: Endomyocardial Injection of Autologous Bone Marrow Cells
Study NCT01150175 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endomyocardial Injection of Plasma
Description: Endomyocardial Injection of Plasma
Study NCT00533143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non invasive ventilation (NIV)
Description: NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
Study NCT03175354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
Description: Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
Study NCT03175354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-101 Gel 5% and ALX-101 Gel Vehicle
Description: Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
Study NCT03804736 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT-c
Description: Patients in the FMT-c receive FMT-c (15 capsules every 12 h for 2 days)
Study NCT03804736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT-c Lactobacillus
Description: Patients in the FMT-c Lactobacillus receive FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
Study NCT04511832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.
Study NCT01247636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance- training and home-exercise
Description: Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
Study NCT01247636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance-training and home-exercise
Description: The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
Study NCT03078374 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: Reduced dosage to obtain lower INR range
Study NCT01161043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor wear
Description: All subjects to wear sensors
Study NCT01670539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HomMed Telemonitor
Description: A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses.
Study NCT05223634 — intervention group
Intervention type: OTHER
Intervention: Collection of oral and/or nasal samples
Description: Collection of oral and/or nasal samples after SOC test performed
Study NCT03280654 — intervention group
Intervention type: OTHER
Intervention: overactive bladder
Description: Association between groups and over active bladder symptoms
Study NCT02783443 — intervention group
Intervention type: OTHER
Intervention: General anesthesia
Description: General anesthesia
Study NCT02783443 — intervention group
Intervention type: OTHER
Intervention: Regional anesthesia
Description: Regional anesthesia
Study NCT01648790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel ODT1 - Tablet
Description: Administered orally as tablet.
Study NCT01648790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel ODT2 - Tablet
Description: Administered orally as tablet.
Study NCT01648790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel ODT2 - Suspension
Description: Administered orally as suspension.
Study NCT01232543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 0405
Description: Product 0405 will be administered topically, twice daily for 28 days.
Study NCT02665052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-Based BATRAC plus TTT
Description: Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
Study NCT02665052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lab-based BATRAC plus TTT
Description: Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.
Study NCT02665052 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Entry Usual Care
Description: Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
Study NCT00424749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients received 4 weekly doses of rituximab 375 mg/m\^2.
Study NCT00424749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
Study NCT01257815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study NCT00938808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: day formula diet
Description: The Cambridge Programme. Formula diet
Study NCT00938808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: day formula diet
Description: The Cambridge Programme. Formula diet
Study NCT01990638 — intervention group
Intervention type: OTHER
Intervention: exercise capacity test
Study NCT00446524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + Amlodipine besilate
Description: During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
Study NCT02584322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery pathway
Description: The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
Study NCT02709499 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 0J LLLT
Description: perform with the machine off
Study NCT02709499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6J LLLT
Description: irradiation will be perform with 4J
Study NCT03390543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sono with Device
Description: In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, both the device and sono-guided internal jugular vein catheterization was performed.
Study NCT03390543 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sono only
Description: In Group S, simple needle guide device was not attached to the sono probe. After induction of anesthesia, only sono-guided internal jugular vein catheterization was performed.
Study NCT03901105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flortaucipir F18
Description: No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES
Study NCT03901105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain
Study NCT00619970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Healthy controls will receive one lactulose breath test to assess for SIBO
Study NCT00619970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xifaxan
Description: xifaxan 550mg TID x10days
Study NCT00619970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo TID x 10days
Study NCT00619970 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lactulose Breath Test
Description: Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
Study NCT00619970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
Study NCT01750320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Koning Breast CT-guided Biopsy
Description: The breast will be positioned and stabilized in the grid/compression device. Four KBCT scans will be taken to guide the vacuum-assisted biopsy procedure.
Study NCT00520728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Time Use Intervention
Description: 12 week behavioral intervention administered by Occupational Therapists.
Study NCT03789461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: FMT infusion (100-200ml) and Mucosal Microbiota Assessment (To assess the fecal and mucosal microbiota before and after FMT)
Study NCT04029220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Peer Navigation
Description: Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
Study NCT04029220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Peer Navigation
Description: Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
Study NCT03868540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: tablet
Study NCT03868540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study NCT03434340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peppermint essential oil
Description: 2 drops applied on a nasal strip
Study NCT03434340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: 1mg intravenous injection
Study NCT03434340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: 1mg intravenous injection
Study NCT03434340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4mg intravenous injection
Study NCT03434340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4mg intravenous injection
Study NCT03163251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: READ-SG Sessions
Description: In the Internal Medicine residency program at Columbia University Medical Center, PGY-1 trainees receive an hour of protected time to attend a monthly peer-facilitated small group session, outlined above. PGY-2 and 3 trainees have a similar combined session separate from the PGY-1s. Facilitators are chosen by the READ-SG Committee, which is comprised of Mark P. Abrams (Director, Co-Investigator), Evelyn Granieri (Faculty Advisor, PI), a Chief Resident from the program (Program Liaison), and the facilitators.
Study NCT04862533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Alanine
Description: Participants will receive 1150mg of beta-alanine three times a day
Study NCT04862533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo three times a day
Study NCT04862533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Description: Participants in both groups will undergo PFMT training program
Study NCT04042870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Loosening Yoga
Description: Sukshma Vyayama Joint Loosening Yoga was practiced Monday - Friday for four weeks. Each session included twelve joint loosening exercises performed in a chair, each performed 10 times with mindful awareness of physical movements and breath synchronization. Sessions lasted 15 minutes.
Study NCT04206020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SkQ1 Vehicle Solution
Description: SkQ1 Ophthalmic Solution Vehicle
Study NCT04206020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SkQ1 Ophthalmic Solution
Description: SkQ1 Ophthalmic Solution
Study NCT00572026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Transdermal System
Description: Daytrana wear time up to 15 hours
Study NCT03714191 — intervention group
Intervention type: OTHER
Intervention: Patient Outcomes
Description: The intervention includes different versions of the BPA design and message.
Study NCT03714191 — intervention group
Intervention type: OTHER
Intervention: Billing documentation
Description: The intervention includes different versions of the BPA design and message.
Study NCT03714191 — intervention group
Intervention type: OTHER
Intervention: Regulatory
Description: The intervention includes different versions of the BPA design and message.
Study NCT02775084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: 4 capsules twice daily with food for 6 weeks